News | June 08, 2024
Borosil Scientific debuts on stock exchange
This strategic decision will unlock significant value for our scientific and industrial products business
This strategic decision will unlock significant value for our scientific and industrial products business
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
Establishing Asymchem’s first manufacturing footprint in Europe
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
Subscribe To Our Newsletter & Stay Updated
